Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to micen

Toxicology Letters

Volumn 199, Issue 2, 2010, Pages 144-152

  Choi, Mina ^a   Cho, Minjung ^a   Han, Beom Seok ^b   Hong, Jin ^a   Jeong, Jayoung ^a   Park, Sangjin ^c   Cho, Myung Haing ^d,e   Kim, Kwangmeyung ^c   Cho, Wan Seob ^c,f  

^a National Institute of Food and Drug Safety Evaluation   (South Korea)

^b Hoseo University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d Seoul National University   (South Korea)

^e Seoul National University   (South Korea)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Elimination; Hydrophobically modified glycol chitosan; Intratracheal instillation; Pulmonary delivery vehicle; Tissue distribution

Indexed keywords

CHITOSAN; GLYCOL; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EVALUATION; HALF LIFE TIME; HYDRODYNAMICS; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; URINARY EXCRETION; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; LUNG; PATHOLOGY; TOXICITY;

ANIMALS; CHITOSAN; LUNG; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PNEUMONIA; TISSUE DISTRIBUTION;

MUS;

EID: 77957951953     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.08.016     Document Type: Article

References (38)

1. Auffan M., Rose J., Bottero J.Y., Lowry G.V., Jolivet J.P., Wiesner M.R. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat. Nanotechnol. 2009, 4:634-641.
2. Buxton D. The promise of nanotechnology for heart, lung and blood diseases. Expert Opin. Drug Deliv. 2006, 3:173-175.
3. Card J.W., Zeldin D.C., Bonner J.C., Nestmann E.R. Pulmonary applications and toxicity of engineered nanoparticles. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L400-411.
4. Cho W.S., Cho M., Jeong J., Choi M., Cho H.Y., Han B.S., Kim S.H., Kim H.O., Lim Y.T., Chung B.H. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol. Appl. Pharmacol. 2009, 236:16-24.
5. Cho W.S., Cho M., Kim S.R., Choi M., Lee J.Y., Han B.S., Park S.N., Yu M.K., Jon S., Jeong J. Pulmonary toxicity and kinetic study of Cy5.5-conjugated superparamagnetic iron oxide nanoparticles by optical imaging. Toxicol. Appl. Pharmacol. 2009, 239:106-115.
6. Cho W.S., Choi M., Han B.S., Cho M., Oh J., Park K., Kim S.J., Kim S.H., Jeong J. Inflammatory mediators induced by intratracheal instillation of ultrafine amorphous silica particles. Toxicol. Lett. 2007, 175:24-33.
7. Cho, W.S., Duffin, R., Poland, C.A., Howie, S.E., Macnee, W., Bradley, M., Megson, I.L., Donaldson, K., 2010. Metal oxide nanoparticles induce unique inflammatory footprints in the lung; important implications for nanoparticle testing. Environ. Health Perspect. doi:10.1289/ehp.1002201.
8. Cho Y.W., Park S.A., Han T.H., Son D.H., Park J.S., Oh S.J., Moon D.H., Cho K.J., Ahn C.H., Byun Y., Kim I.S., Kwon I.C., Kim S.Y. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials 2007, 28:1236-1247.
9. Cleland J.L., Daugherty A., Mrsny R. Emerging protein delivery methods. Curr. Opin. Biotechnol. 2001, 12:212-219.
10. Donaldson K., Borm P.J., Oberdorster G., Pinkerton K.E., Stone V., Tran C.L. Concordance between in vitro and in vivo dosimetry in the proinflammatory effects of low-toxicity, low-solubility particles: the key role of the proximal alveolar region. Inhal. Toxicol. 2008, 20:53-62.
11. Gonda I. The ascent of pulmonary drug delivery. J. Pharm. Sci. 2000, 89:940-945.
12. Gonda I. Peptides and proteins: pulmonary absorption. Encyclopedia of Pharmaceutical Technology 2007, Informa Healthcare, USA.
13. Heinemann L., Traut T., Heise T. Time-action profile of inhaled insulin. Diabet. Med. 1997, 14:63-72.
14. Hyung Park J., Kwon S., Lee M., Chung H., Kim J.H., Kim Y.S., Park R.W., Kim I.S., Bong Seo S., Kwon I.C., Young Jeong S. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials 2006, 27:119-126.
15. Jin H., Kim T.H., Hwang S.K., Chang S.H., Kim H.W., Anderson H.K., Lee H.W., Lee K.H., Colburn N.H., Yang H.S., Cho M.H., Cho C.S. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol. Cancer Ther. 2006, 5:1041-1049.
16. Kim J.H., Kim Y.S., Park K., Lee S., Nam H.Y., Min K.H., Jo H.G., Park J.H., Choi K., Jeong S.Y., Park R.W., Kim I.S., Kim K., Kwon I.C. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control. Release 2008, 127:41-49.
17. Kim J.S., Yoon T.J., Yu K.N., Noh M.S., Woo M., Kim B.G., Lee K.H., Sohn B.H., Park S.B., Lee J.K., Cho M.H. Cellular uptake of magnetic nanoparticle is mediated through energy-dependent endocytosis in A549 cells. J. Vet. Sci. 2006, 7:321-326.
18. Kim K., Kwon S., Park J.H., Chung H., Jeong S.Y., Kwon I.C., Kim I.S. Physicochemical characterizations of self-assembled nanoparticles of glycol chitosan-deoxycholic acid conjugates. Biomacromolecules 2005, 6:1154-1158.
19. Klingler C., Muller B.W., Steckel H. Insulin-micro- and nanoparticles for pulmonary delivery. Int. J. Pharm. 2009, 377:173-179.
20. Kumar M., Behera A.K., Lockey R.F., Zhang J., Bhullar G., De La Cruz C.P., Chen L.C., Leong K.W., Huang S.K., Mohapatra S.S. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum. Gene Ther. 2002, 13:1415-1425.
21. Kumar M., Kong X., Behera A.K., Hellermann G.R., Lockey R.F., Mohapatra S.S. Chitosan IFN-gamma-pDNA nanoparticle (CIN) therapy for allergic asthma. Genet. Vaccin. Ther. 2003, 1:3.
22. Kwon J.T., Hwang S.K., Jin H., Kim D.S., Minai-Tehrani A., Yoon H.J., Choi M., Yoon T.J., Han D.Y., Kang Y.W., Yoon B.I., Lee J.K., Cho M.H. Body distribution of inhaled fluorescent magnetic nanoparticles in the mice. J. Occup. Health 2008, 50:1-6.
23. Laube B.L., Benedict G.W., Dobs A.S. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. J. Aerosol Med. 1998, 11:153-173.
24. Lipka J., Semmler-Behnke M., Sperling R.A., Wenk A., Takenaka S., Schleh C., Kissel T., Parak W.J., Kreyling W.G. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 2010, 31:6574-6581.
25. Lu S., Duffin R., Poland C., Daly P., Murphy F., Drost E., Macnee W., Stone V., Donaldson K. Efficacy of simple short-term in vitro assays for predicting the potential of metal oxide nanoparticles to cause pulmonary inflammation. Environ. Health Perspect. 2009, 117:241-247.
26. Martin L., Wilson C.G., Koosha F., Tetley L., Gray A.I., Senel S., Uchegbu I.F. The release of model macromolecules may be controlled by the hydrophobicity of palmitoyl glycol chitosan hydrogels. J. Control. Release 2002, 80:87-100.
27. Niven R.W. Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst. 1995, 12:151-231.
28. O'Hagan D.T., Illum L. Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. Crit. Rev. Ther. Drug Carrier Syst. 1990, 7:35-97.
29. Park K., Kim J.H., Nam Y.S., Lee S., Nam H.Y., Kim K., Park J.H., Kim I.S., Choi K., Kim S.Y., Kwon I.C. Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J. Control. Release 2007, 122:305-314.
30. Pison U., Welte T., Giersig M., Groneberg D.A. Nanomedicine for respiratory diseases. Eur. J. Pharmacol. 2006, 533:341-350.
31. Sajja H.K., East M.P., Mao H., Wang Y.A., Nie S., Yang L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr. Drug Discov. Technol. 2009, 6:43-51.
32. Sanvicens N., Marco M.P. Multifunctional nanoparticles-properties and prospects for their use in human medicine. Trends Biotechnol. 2008, 26:425-433.
33. Sarlo K., Blackburn K.L., Clark E.D., Grothaus J., Chaney J., Neu S., Flood J., Abbott D., Bohne C., Casey K., Fryer C., Kuhn M. Tissue distribution of 20nm, 100nm and 1000nm fluorescent polystyrene latex nanospheres following acute systemic or acute and repeat airway exposure in the rat. Toxicology 2009, 263:117-126.
34. Sung J.C., Pulliam B.L., Edwards D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007, 25:563-570.
35. Tomoda K., Ohkoshi T., Hirota K., Sonavane G.S., Nakajima T., Terada H., Komuro M., Kitazato K., Makino K. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf. B: Biointerfaces 2009, 71:177-182.
36. Tsapis N., Bennett D., Jackson B., Weitz D.A., Edwards D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12001-12005.
37. Tseng C.L., Su W.Y., Yen K.C., Yang K.C., Lin F.H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
38. Zhu M.T., Feng W.Y., Wang Y., Wang B., Wang M., Ouyang H., Zhao Y.L., Chai Z.F. Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide nanoparticles in rats and the potential health risk assessment. Toxicol. Sci. 2009, 107:342-351.